#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics and cholesterol regulation

KEYPOINTS

• 01

  Lipids do not float free in plasma—they ride inside lipoproteins.

  Dayspring credits physicist John Gofman (the transcript sometimes says 'Hoffman') with mid-century ultracentrifuge work showing hydrophobic lipids must be packaged. Learn that first, he says, or every later cholesterol debate will be confused. Plasma is water; triglycerides and cholesteryl esters are not. Without apolipoproteins and phospholipid coats, the cargo would oil-slick out of solution.

• 02

  There are separate lipoprotein lineages, not one maturation ladder.

  You do not climb chylomicron → VLDL → IDL → LDL → HDL as a single sequence. Chylomicrons are gut-derived triglyceride carriers; VLDL/LDL are liver-apoB lineage; HDL is its own system. Mixing those stories produces nonsense clinical advice. Dayspring is emphatic about that semantic hygiene because patients hear 'LDL turns into HDL' folklore that no pathway diagram supports.

• 03

  LDL-C measures cholesterol cargo; LDL-P / apoB count the ships.

  A 'direct LDL-C' assay quantifies cholesterol inside LDL particles. NMR LDL-P reports particle concentration in nmol/L. ApoB counts apoB-containing particles. Discordance—low cholesterol per particle but high particle number—is exactly where risk hides from a standard panel. When particles are cholesterol-poor but numerous—common in insulin resistance—LDL-C underestimates risk and apoB corrects it.

• 04

  Ultracentrifugation is the conceptual gold standard almost nobody uses clinically.

  Separating fractions and measuring cholesterol in each is too slow for routine care, so chemistry assays and NMR shortcuts evolved. Framingham-era HDL assays were an early practical win; modern NMR still cannot perfectly distinguish a huge chylomicron from a huge VLDL by size alone. Chemists built direct assays precisely because nobody could centrifuge every patient sample the way research labs once did.

• 05

  Sterol vocabulary matters: cholesterol, stanols, zoosterols, phytosterols.

  Cholesterol has a double bond at carbons 5–6 and a hydroxyl at carbon 3. Saturating that bond yields a stanol. Plant foods bring dozens of phytosterols (campesterol, stigmasterol, and others). Those markers help sort synthesis vs absorption stories in advanced testing. Mislabeling a stanol as cholesterol on a slide is the kind of error that still shows up in papers Dayspring referees, which is why he drills structure.

• 06

  ABC transporters move sterols in and out of cells and gut lumen.

  ABCA1 helps seed nascent HDL; ABCG5/G8 efflux sterols (including plant sterols) back into the gut. People vary widely in sterol absorption—Dayspring cites ranges from modest (~20%) to very high (reports into the 60%+ range)—so the same diet is not the same internal exposure. If ABCG5/G8 is sluggish, phytosterols accumulate; sitosterolemia is the extreme teaching case for why efflux genes matter.

• 07

  The brain makes its own cholesterol; plasma LDL is not its delivery truck.

  Neurons and glia synthesize what they need behind the blood–brain barrier. That fact reframes why crashing plasma LDL pharmacologically is not the same as starving the CNS of cholesterol. That disconnect also explains why neurologic fear-mongering about 'low cholesterol starving the brain' usually misunderstands compartmentalization.

• 08

  Acute illness wrecks a lipid panel's meaning.

  Peter noticed HDL plunging in ICU patients under extreme stress and kept rechecking it. Inflammatory and metabolic shifts move lipids transiently—so never make chronic risk decisions off an admission panel. Steroidogenic tissues still need cholesterol for hormones, but an ICU draw is the wrong moment to invent a lifelong HDL deficiency story.

• 09

  Cholesterol synthesis pathways (Bloch / Kandutsch–Russell) are not trivia.

  Multiple routes and crossovers exist; cells still end at the cholesterol molecule they need. Understanding synthesis vs absorption helps interpret precursor sterols on advanced panels and why some drugs hit production while others hit gut uptake. Nobel politics aside (Bloch/Lynen vs later pathway workers), clinicians mainly need to know production and absorption can be independently high or low.

• 10

  This Part II is the 101 before later clinical application episodes.

  Dayspring is one of Peter's core lipid mentors. The episode deliberately stays on structure, measurement, and vocabulary so later talks about residual risk, remnants, and therapy have a shared language. Listeners should treat this installment as vocabulary bootcamp before Parts III–V get more applied.